Iron oxide nanoparticle compound and preparation method and application thereof

Abstract

The invention provides an iron oxide nanoparticle compound (IONPs-PEG-MCCtriple scabs). The iron oxide nanoparticle compound comprises pegylated iron oxide nanoparticles and three single-chain antibodies for surface modification. The three single-chain antibodies are all coupled with the pegylated iron oxide nanoparticles and include an anti-MUC4 single-chain antibody, an anti-CEACAM6 single-chainantibody and an anti-CD44v6 single-chain antibody. The iron oxide nanoparticle compound is a diagnosis and treatment integrated dual-function nanomaterial, can be used as a novel efficient pancreaticcancer MRI contrast medium and can also be used for pancreatic cancer treatment due to the anti-pancreatic-cancer effect.

Description

technical field [0001] The invention relates to an iron oxide nanoparticle composite, a preparation method and an application thereof. Background technique [0002] Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest human cancers, with a 5-year relative survival rate of approximately 6%, and the seventh leading cause of cancer death. This may be due to the severe local invasion or distant metastasis at the time of diagnosis, and the lack of effective treatment for advanced PDAC. So far, one of the important research directions to improve the prognosis of PDAC is the precise diagnosis of pancreatic cancer. MRI, especially enhanced MR contrast imaging, is an important tool for the detection and diagnosis of pancreatic lesions. In MR enhanced contrast imaging, the development of sensitive High-efficiency contrast agents are one of the important directions in MR-enhanced imaging research. [0003] In recent years, antibody therapy has made great progress in the fi...

AI Technical Summary

Problems solved by technology

The correlation between tumor-associated molecular markers on the surface of the cell membrane and tumors is the basis for diagnosis or treatment of molecular markers. The stronger the correlation between a marker and a certain tumor, the higher its sensitivity to the tumor. The relationship between a single molecular marker and a tumor There are certain limitations in the correlation of molecular markers. There is heterogeneity in the expression levels of molecular markers in tumor cells. Some cells may express marker 1, but not or lowly express marker 2. During treatment, tumor cells that do not express the corresponding markers will not be detected or identified, resulting in a decrease in sensitivity, which is also one of the basic reasons for the insufficient sensitivity of tumor-related molecular markers on the cell membrane surface to diagnose or treat tumors

Images